Get the Stockscreener App
0.2614
2.73%
-0.0062
Vistagen Therapeutics Inc stock is traded at $0.2614, with a volume of 814.01K.
It is down -2.73% in the last 24 hours and up +13.57% over the past month.
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
See More
Previous Close:
$0.2676
Open:
$0.27
24h Volume:
814.01K
Relative Volume:
0.21
Market Cap:
$11.60M
Revenue:
$1.04M
Net Income/Loss:
$-67.50M
P/E Ratio:
-0.136
EPS:
-1.9222
Net Cash Flow:
$-60.67M
1W Performance:
-1.33%
1M Performance:
+13.57%
6M Performance:
-50.89%
1Y Performance:
-92.14%
1-Day Range:
$0.2573
$0.27
1-Week Range:
$0.2511
$0.2765
52-Week Range:
$0.198
$5.14
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
Name
Vistagen Therapeutics Inc
Sector
Industry
Phone
650-577-3600
Address
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare VTGN vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
0.2614 | 11.88M | 1.04M | -67.50M | -60.67M | -1.9222 |
VRTX
Vertex Pharmaceuticals Inc
|
515.23 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
807.36 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
991.43 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.76 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.49 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-25 | Downgrade | Jefferies | Buy → Hold |
| Dec-17-25 | Downgrade | Maxim Group | Buy → Hold |
| Dec-17-25 | Downgrade | Stifel | Buy → Hold |
| Dec-17-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-07-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-07-23 | Upgrade | Maxim Group | Hold → Buy |
| Jul-22-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-22-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-22-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| May-20-21 | Initiated | Robert W. Baird | Outperform |
| Feb-18-21 | Initiated | Jefferies | Buy |
| Jan-04-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-27-18 | Initiated | Maxim Group | Buy |
| Feb-08-18 | Reiterated | Chardan Capital Markets | Buy |
| Mar-28-17 | Initiated | Maxim Group | Buy |
View All
Vistagen Therapeutics Inc Stock (VTGN) Latest News
VistaGen Therapeutics earnings missed by $0.05, revenue topped estimates - Investing.com Canada
Vistagen Therapeutics: Runway To Fund Operations Into 2027 >VTGN - Moomoo
William Blair Maintains VistaGen Therapeutics(VTGN.US) With Hold Rating - Moomoo
Vistagen Therapeutics Releases Q1 2027 Financial Results - AlphaStreet
Vistagen Therapeutics (VTGN): OrbiMed reports 0.0% beneficial ownership in latest 13G/A - Stock Titan
Vistagen Therapeutics (VTGN) investor Chen Yu reports 6.7% warrant-based stake - Stock Titan
Vistagen Therapeutics (VTGN) flags going concern risk amid Q1 loss and Nasdaq pressure - Stock Titan
Vistagen Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2026 - marketscreener.com
Vistagen Therapeutics (VTGN) investor reports 4.24M-share, 9.9% stake - Stock Titan
Form 8K VistaGen Therapeutics Inc For: 14 August By Investing.com - Investing.com Nigeria
Vistagen reports Q1 FY2027: $1.48M revenue, $13.0M net loss, $31.7M cash at June 30, 2026 - TradingView
Vistagen (VTGN) narrows quarterly loss, eyes FDA path after mixed fasedienol data - Stock Titan
Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update - GlobeNewswire
Press Release: Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update - Moomoo
VistaGen Granted Nasdaq Extension to Regain Bid Compliance - The Globe and Mail
Vistagen (Nasdaq: VTGN) posts Phase 2 fasedienol efficacy signals - Stock Titan
Vistagen (VTGN) Reports Phase 2 Social Anxiety Study Results Ami - GuruFocus
Vistagen reports phase 2 social anxiety trial results - Investing.com
Vistagen's second fasedienol dose showed no new safety findings - Stock Titan
Vistagen Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Vistagen Therapeutics (NASDAQ: VTGN) granted 180-day Nasdaq bid-price extension - Stock Titan
The Bull Lives Below $1: PRSO, ENSC, TNMG, QNME Stocks to Watch - financialcontent.com
SRX Global (NYSE American: SRXH) Acquires Stake in Vistagen Therapeutics - TipRanks
SRX Global (SRXH) Acquires Stake in Vistagen Therapeutics - finance.yahoo.com
Vistagen Therapeutics, Inc. Stockholders with Large Losses in VTG - The National Law Review
VTGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
SRX Global Acquires Stake in Vistagen Therapeutics - Yahoo Finance
SRX Global Inc. Acquires Undisclosed Stake in Vistagen Therapeutics - citybiz
Press Release: SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN) - Moomoo
SRX Global acquires Vistagen stake, terms undisclosed - grafa.com
SRX Global (NYSE American: SRXH) Acquires Stake In Vistagen Therapeutics - Menafn
SRX Global acquires stake in Vistagen Therapeutics - Bitget
Vistagen Therapeutics Inc expected to post a loss of 36 cents a shareEarnings Preview - TradingView
VTGN FINAL DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages V - The National Law Review
VistaGen Therapeutics Appoints Douglas Williamson to Board - The Globe and Mail
Form 4 VistaGen Therapeutics Inc For: 31 July By Investing.com - Investing.com Nigeria
Vistagen appoints Douglas Williamson to board of directors By Investing.com - Investing.com Nigeria
Vistagen Therapeutics (Nasdaq: VTGN) names Douglas J. Williamson to board - Stock Titan
Vistagen Appoints Douglas J. Williamson to its Board of Directors - GlobeNewswire
Vistagen appoints Douglas Williamson to board of directors - Investing.com
Vistagen Therapeutics Inc (VTGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Vistagen Therapeutics, Inc. Revenue Breakdown – BMV:VTGN - TradingView
TradingKey - TradingKey
VTGN|Vistagen Therapeutics Inc|Price:0.226|Chg%:+0.000 - TradingKey
VTGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds - The National Law Review
VTGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
This Stock Lost 71% Of Value After Anxiety Therapy Missed Key Goals – But Retail Believes It’s Oversold, Says Won’t Panic-Sell - Stocktwits
VTGN News | VISTAGEN THERAPEUTICS INC (NASDAQ:VTGN) - ChartMill
Is Vistagen Therapeutics, Inc. (VTGN) Stock Facing New Challenges After PALISADE-4 Clinical Trial Results? - Yahoo Finance
VTGN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
VTGN Stockholders Have Opportunity to Lead Vistagen Therapeutics - The National Law Review
Vistagen Therapeutics Inc Stock (VTGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.00%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):